Dynamic PD-L1 Regulation Shapes Tumor Immune Escape and Response to Immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.Journal of experimental & clinical cancer research : CR · 2026
   Article
2. Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization.Scientific reports · 2026
   Article
3. Do Metastatic Cells Arise from PD-L1International journal of molecular sciences · 2026
   Review
4. A Minimal Model Framework for Robust CAR-T Cell and Oncolytic Virus Combination Therapy.Research square · 2026
   Article

Corrections and comments

• Update of
  Dynamic PD-L1 Regulation Shapes Tumor Immune Escape and Response to Immunotherapy.2025

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as